MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.550
-0.120
-4.49%
After Hours: 2.640 +0.09 +3.53% 19:49 05/10 EDT
OPEN
2.620
PREV CLOSE
2.670
HIGH
2.620
LOW
2.350
VOLUME
3.76M
TURNOVER
--
52 WEEK HIGH
6.48
52 WEEK LOW
1.870
MARKET CAP
34.51M
P/E (TTM)
-1.0256
1D
5D
1M
3M
1Y
5Y
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.
Benzinga · 16h ago
AUPH, MGI, EPZM and FROG among midday movers
Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharm...
Seekingalpha · 3d ago
Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings
PR Newswire · 04/29 12:30
Phio Pharmaceuticals Announces Upcoming Data Presentations At ASGCT And ASCO Annual Meetings
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today
Benzinga · 04/29 11:58
Phio Pharma Saturday Morning Announced Presentation Of In Vivo Data Showing Strong Tumor Control For Intratumoral Delivery Of INTASYL RNAi Targeting PD-1 At American Association For Cancer Research Conference
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today
Benzinga · 04/12 14:12
Phio Pharma's Intasyl Platform Shows Promising Tumor Control Activity In Animal Studies
Benzinga · 04/12 11:33
Phio Pharmaceuticals Shares See Volume; Co Received Intention To Grant European Patent Titled 'RNA INTERFERENCE IN OCULAR INDICATIONS'
https://register.epo.org/application?number=EP19168667&lng=en&tab=main
Benzinga · 03/30 14:17
The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 25)
Benzinga · 03/26 11:28
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHIO. Analyze the recent business situations of Phio Pharmaceuticals Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PHIO stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 959.49K
% Owned: 7.09%
Shares Outstanding: 13.53M
TypeInstitutionsShares
Increased
2
85.18K
New
6
200.24K
Decreased
0
0
Sold Out
6
80.33K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Director
Robert Bitterman
President/Chief Executive Officer/Chief Operating Officer
Gerrit Dispersyn
Other
John Barrett
Director
Geert Cauwenbergh
Independent Director
H. Paul Dorman
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
No Data
About PHIO
Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.